Cite
HARVARD Citation
Bhatia, A. et al. (2017). Double‐blind, randomized phase 3 trial of low‐dose 13‐cis retinoic acid in the prevention of second primaries in head and neck cancer: Long‐term follow‐up of a trial of the Eastern Cooperative Oncology Group‐ACRIN Cancer Research Group (C0590). Cancer. 123 (23), pp. 4653-4662. [Online].